SCHEMBL6176759

SCHEMBL6176759

CC(=O)Nc1nc(-c2ccc(NC(=O)CN(C(=O)c3ccc(F)cc3)c3ccc4c(c3)OCO4)cc2)cs1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 6/20 0.57
▸ NPC1 O15118 5/20 0.57
▸ MAPT P10636 6/20 0.51
▸ LMNA P02545 6/20 0.51
▸ SMN1; SMN2 Q16637 6/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ HTT P42858 2/20 0.49
▸ TSHR P16473 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ GAA P10253 1/20 0.49
▸ KMT2A Q03164 5/20 0.46
▸ MEN1 O00255 4/20 0.46
▸ NFKB1 P19838 2/20 0.46
▸ NFKB2 Q00653 2/20 0.46
▸ RELA Q04206 2/20 0.46
▸ ROCK1 Q13464 1/20 0.46
▸ MAPK1 P28482 1/20 0.45
▸ ALOX5 P09917 1/20 0.44
▸ GSTO1 P78417 1/20 0.44
▸ CFTR P13569 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6175614 0.91 MAPT (0.49) RAB9ANPC1MAPTLMNASMN1; SMN2
SCHEMBL6172214 0.89 MAPT (0.51) RAB9AMAPTLMNASMN1; SMN2KDM4E
SCHEMBL27601341 0.87 MAPT (0.47) RAB9ANPC1MAPTLMNASMN1; SMN2
SCHEMBL27601314 0.87 KMT2A (0.51) RAB9ANPC1MAPTLMNASMN1; SMN2
SCHEMBL6174882 0.84 POLB (0.49) RAB9ANPC1MAPTLMNASMN1; SMN2
SCHEMBL6176630 0.77 RAB9A (0.65) RAB9ANPC1MAPTLMNASMN1; SMN2
Hydrochloric Acid SCHEMBL6173338 0.75 RAB9A (0.50) RAB9ANPC1MAPTLMNASMN1; SMN2
SCHEMBL6174603 0.75 MAPT (0.53) RAB9AMAPTLMNASMN1; SMN2HTT
SCHEMBL6173268 0.74 RAB9A (0.43) RAB9ANPC1MAPTSMN1; SMN2KDM4E
SCHEMBL27583802 0.73 KMT2A (0.48) RAB9ANPC1MAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949543-B2 Amide derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-27 — — US disclosed
EP-1340750-B1 AMIDE DERIVATIVES YAMANOUCHI PHARMA CO LTD (JP) 2005-08-17 — — EP disclosed
US-20040034232-A1 Amide derivative ASTELLAS PHARMA INC. (JP) 2004-02-19 — — US disclosed
CN-1473157-A Amide derivatives ֮����ҩ��ʽ���� 2004-02-04 — — CN disclosed
EP-1340750-A1 AMIDE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-09-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034232-A1 Amide derivative HDAC2, ZC3HAV1, HDAC4 RAB9A 1475/4885NPC1 3690/4885MAPT 1746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback